KOSDAQChemicals352940

Enbioco

₩1,850▼ 1.70%2026-11-18 close
Market Cap
₩20.1B
Turnover
₩39,345,162
Volume
20K
Shares out.
10.9M
PER
112.9×
PBR
0.5×
EPS
₩17
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Nonghyup Channel Growth Meets Swinging Quarterly Profits

Enbioco's annual profit has been positive since 2024, but quarterly results swung to an operating loss in the third quarter of 2026.

  1. 1

    On the 2025 filing, revenue was KRW 34 billion (down 4.8% year on year) and operating profit was KRW 917 million (down 34.7%).

  2. 2

    Operating profit of KRW 3.13 billion in Q1 2026 gave way to an operating loss of KRW 1.93 billion in Q3 2026.

  3. 3

    Net income attributable to controlling shareholders over the last four quarters totals KRW 181 million, a small earnings base.

  4. 4

    On August 13, 2026, the company said Nonghyup channel sales and herbicide and fungicide exports drove first-half growth (preliminary).

  5. 5

    The debt ratio fell from 87.9% in 2022 to 63.2% in 2025, and total equity at the end of 2025 was KRW 42.4 billion.

02

Business structure

Enbioco was founded in 1997 to manufacture and sell agricultural chemicals and listed on KOSDAQ in 2020. Its core products are a lime-sulfur formulation, a sulfur-based eco-friendly crop protection product, a broad-spectrum insecticide, and fungicide, insecticide and herbicide lines plus fertilizers.

The company says it has developed and registered 182 products over the past ten years and is expanding labor-saving formulations and eco-friendly crop protectants. Domestic sales run mainly through the Nonghyup agricultural cooperative system and local agricultural wholesalers, supported by 10 domestic branches.

A supply contract with Nonghyup Economic Group signed on February 13, 2026 has a contract value of KRW 9.31 billion and runs through December 31, 2026. The company said first-half 2026 Nonghyup channel sales rose 71% year on year, as announced on August 13, 2026.

Overseas, herbicide exports rose 567% and fungicide exports rose 153% in the same period, according to the company.

In new drugs, Enbioco plans to start full-scale commercialization in 2026 of a fungicide drug candidate selected with the Korea Research Institute of Chemical Technology under a Ministry of Trade, Industry and Energy project running since 2020.

The company also plans to expand into supplying active ingredients to other producers. According to company statements from 2024, the global fungicide market is led by Syngenta, Corteva, Bayer and BASF, and resistance to existing substances is raising demand for new drugs.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩3.9B-₩1.3B−34.1%
2025Q4₩7.7B-₩700M−9.5%
2026Q1₩14.1B₩3.1B22.1%
2026Q2₩10.4B₩200M1.6%
2026Q3₩4.2B-₩1.9B−45.5%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩34.2B-₩4.8B-₩3.4B−14.0%−7.4%87.9%
2023₩34B-₩3.4B-₩6.3B−9.9%−15.5%62.8%
2024₩35.7B₩1.4B₩600M3.9%1.6%63.8%
2025₩34B₩900M₩1B2.7%2.4%63.2%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-14

04

Earnings analysis

Annual revenue on the filings was KRW 34.2 billion in 2022, KRW 34 billion in 2023 (down 0.6%), KRW 35.7 billion in 2024 (up 4.8%) and KRW 34 billion in 2025 (down 4.8%), with 2024 the largest year and 2025 the smallest in the period.

Operating results were an operating loss of KRW 4.78 billion in 2022 and KRW 3.35 billion in 2023, a continued loss with a narrower gap, before a turn to operating profit of KRW 1.41 billion in 2024. Operating profit then fell to KRW 917 million in 2025, down 34.7%.

The operating margin was -14.0% in 2022, -9.9% in 2023, 3.9% in 2024 and 2.7% in 2025. Net income attributable to controlling shareholders was a loss of KRW 3.44 billion in 2022 and a loss of KRW 6.3 billion in 2023, which widened the loss, before turning to a profit of KRW 646 million in 2024.

It rose to KRW 1.01 billion in 2025, up 56.0%, moving in the opposite direction from operating profit. Quarterly revenue went from KRW 3.94 billion in Q3 2025 to KRW 7.66 billion in Q4 2025 (up 94.7% from the prior quarter) and peaked at KRW 14.1 billion in Q1 2026.

Operating profit turned positive at KRW 3.13 billion in Q1 2026, but Q2 2026 operating profit was only KRW 172 million (down 94.5% from the prior quarter).

In Q3 2026, revenue was KRW 4.23 billion (down 59.5% from the prior quarter, up 7.5% year on year) and operating loss was KRW 1.93 billion, a switch to loss and a wider loss year on year.

Net loss attributable to controlling shareholders was KRW 1.5 billion in Q3 2026, the second straight quarter of losses since Q2 2026.

For Q1 2026, a WiseReport company summary said revenue rose slightly on steady sales of core product lines, while operating profit eased slightly on higher costs for formulation products and new drug development.

05

Industry analysis

The crop protection (agrochemical) market where Enbioco operates is a small specialty niche even within the chemicals sector. According to company statements from 2024, the global fungicide market is about USD 20.4 billion, and resistance to existing substances is increasing the need for new drugs.

The company says food shortages from global warming and a rise in invasive pests are increasing demand for new products. In Korea, sales run mainly through the Nonghyup agricultural cooperative system, so terms of supply contracts with sales channels can affect quarterly revenue swings.

Large petrochemical and materials peers such as LG Chem and Lotte Chemical have different business structures, which limits direct comparison. With revenue of about KRW 34 billion in 2025, Enbioco is far smaller than large chemical groups, so its results are relatively more sensitive to swings.

In exports, herbicide and fungicide shipments grew sharply in the first half of 2026, though high growth rates can be affected by a low base in the prior year. In new products, labor-saving formulations and eco-friendly crop protectants are presented as the company's growth pillars.

In a market led by large global players, Enbioco is building its position on its Nonghyup channel and export products.

06

Outlook

The company's stated 2026 target is Nonghyup channel revenue of KRW 12 billion or more. First-half 2026 Nonghyup channel sales rose 71% year on year, and first-half revenue of KRW 24.59 billion (up 10.0%) and operating profit of KRW 3.3 billion (up 10.5%) were announced preliminarily on August 13, 2026.

The first-half totals match the sum of the Q1 and Q2 2026 quarterly results on the filings. However, Q3 2026 revenue of KRW 4.23 billion was down 59.5% from the prior quarter and the company swung to an operating loss of KRW 1.93 billion, so the second half diverged from the first.

The Nonghyup supply contract signed on February 13, 2026 ends on December 31, 2026, so terms after year-end are the next point to watch. In new drugs, the fungicide candidate is moving toward commercialization preparations in 2026, and expanding active ingredient supply is presented as a medium-term strategy.

The timing of commercialization and its revenue contribution have not yet been disclosed in figures. In March 2026, CEO Lee Myung-jae said he would expand share buybacks, citing responsible management and shareholder value.

The 2026 annual report will confirm full-year Nonghyup sales and Q4 results, and whether the first-half growth carried through to year-end.

07

Valuation

PER
112.9×
PBR
0.5×
ROE
0.4%
EPS
₩17
BPS
₩3,972
Dividend per share
₩0

The price-to-book ratio sits below book value per share, which means the stock trades at a discount to net assets. Total equity at the end of 2025 was KRW 42.4 billion, and the controlling shareholders' stake is of the same size.

By contrast, the price-to-earnings ratio appears high on an earnings basis because net income attributable to controlling shareholders over the last four quarters is small.

With a thin earnings base, the multiple moves sharply with the direction of quarterly profit, so reading it depends on whether the recovery in earnings lasts. No dividend has been paid, and shareholder returns are presented as a share buyback plan.

On past results, the company moved from losses in 2022 to a profit in 2024, a recovery in earnings, but the Q3 2026 swing to an operating loss has made the recent trend unstable again. The key fact is that the net-asset-based and earnings-based multiples point in different directions.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-14

08

Bull factors

Joint growth in the Nonghyup channel and exports

First-half 2026 Nonghyup channel sales rose 71% year on year, and the company set a target of KRW 12 billion or more for 2026. Herbicide exports rose 567% and fungicide exports 153% in the same period, according to the company. A Nonghyup supply contract valued at KRW 9.31 billion on the filing shows the scale of this channel.

Operating profit turned positive and balance sheet eased

Operating profit turned from a loss in 2022 to KRW 1.41 billion in 2024, and the operating margin stayed positive at 3.9% in 2024 and 2.7% in 2025. The debt ratio fell from 87.9% in 2022 to 63.2% in 2025, easing balance sheet pressure. Total equity at the end of 2025 was KRW 42.4 billion.

New drug pipeline and share buybacks

The fungicide drug candidate has been developed since 2020 under a Ministry of Trade, Industry and Energy project with KRICT, and commercialization preparations are planned for 2026. The company presents expansion into active ingredient supply as a strategy. In March 2026, CEO Lee Myung-jae said he would expand share buybacks.

09

Bear factors

Sharp swings in quarterly results

Revenue peaked at KRW 14.1 billion in Q1 2026, then fell to KRW 10.4 billion in Q2 and KRW 4.23 billion in Q3, two straight quarters of decline. The company swung to an operating loss of KRW 1.93 billion in Q3 2026, with a net loss attributable to controlling shareholders of KRW 1.5 billion. Net income attributable to controlling shareholders over the last four quarters totals only KRW 181 million.

Thin operating margin and falling revenue

Revenue in 2025 was KRW 34 billion, down 4.8% year on year, and operating profit was KRW 917 million, down 34.7%. The operating margin fell to 2.7% in 2025 from 3.9% in 2024. 2025 was the smallest revenue year in the 2022 to 2025 period, which points to limits on recent growth.

Rising costs and drug investment burden

A WiseReport summary of Q1 2026 cited higher costs for formulation products and new drug development as a reason operating profit eased. The revenue contribution from drug commercialization has not yet been disclosed in figures. The Nonghyup contract ending on December 31, 2026 also reduces revenue visibility.

10

Risk factors

Channel concentration

Sales run mainly through the Nonghyup system, so the contract period ending December 31, 2026 could shape the revenue trend. Renewal terms and whether the KRW 12 billion or more target is reached could widen swings in annual results. The full-year scale of overseas sales is also a point for the annual report.

Drug development costs and commercialization delay

Commercialization preparations for the fungicide candidate began in 2026, yet development costs have already shown up as a factor in operating profit swings. A delayed launch could prolong cost pressure and slow the earnings recovery. Whether product launch and active ingredient supply proceed as planned is the key medium-term risk.

Base effects in export growth and quarterly volatility

Herbicide and fungicide exports rose 567% and 153% in the first half of 2026, but such high growth rates can reflect a low base and may not repeat at the same pace. Quarterly revenue moved from KRW 3.94 billion in Q3 2025 to KRW 14.1 billion in Q1 2026. This volatility lowers the predictability of annual results.

11

What to watch next

  1. December 31, 2026

    The contract period with Nonghyup Economic Group ends. Watch for any extension or follow-on contract disclosure and whether the KRW 12 billion or more Nonghyup target is reached.

  2. March 31, 2027 (statutory filing deadline for the 2026 annual report)

    The 2026 annual report confirms full-year revenue, operating profit, net income attributable to controlling shareholders and Q4 results. Check whether the Q3 loss persisted through year-end and how the operating margin moved from 2.7% in 2025.

  3. May 15, 2027 (statutory filing deadline for the Q1 2027 quarterly report)

    Q1 2027 results are disclosed. Check whether quarterly profit returned to positive after the Q3 2026 loss and how formulation and drug development costs trend.

  4. After year-end 2026 (timing not set)

    Whether specific timelines for commercialization and active ingredient supply are disclosed. Check if the schedule and revenue contribution are presented in figures.

12

Overall view

Enbioco moved from an operating loss in 2022 to operating profit in 2024, an improvement in annual results. However, revenue and operating profit fell in 2025, and quarterly revenue declined for two straight quarters after peaking in Q1 2026.

The company recorded an operating loss of KRW 1.93 billion and a net loss attributable to controlling shareholders of KRW 1.5 billion in Q3 2026, widening losses.

The company's preliminary announcement that Nonghyup channel and herbicide and fungicide exports drove first-half growth is consistent with the sum of the quarterly filings, so it is a useful reference.

Yet first-half strength did not carry into the second half, making revenue after the Nonghyup contract ends the key variable. Drug commercialization preparations and share buybacks are presented as medium-term and shareholder return elements, but their revenue contribution has not yet been disclosed in figures.

Valuation shows a discount to net assets alongside a high earnings-based multiple, and the reading depends on whether the earnings recovery lasts. The next checkpoints are the full-year results in the 2026 annual report and the Q1 2027 quarterly report.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 17 more articles and sources
  1. comp.fnguide.com
  2. comp.wisereport.co.kr
  3. view.asiae.co.kr
  4. pharmnews.com
  5. view.asiae.co.kr
  6. digitaltoday.co.kr
  7. stockcatcher.co.kr
  8. pharmnews.com
  9. edaily.co.kr
  10. datatooza.com
  11. newspim.com
  12. tradingkey.com
  13. eugenefn.com
  14. securities.miraeasset.com
  15. kr.investing.com
  16. panabee.com
  17. finance.yahoo.com

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis